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Case report
Two cases of possible transmitted
drug-resistant HIV: likely HIV
superinfection and unmasking of
pre-existing resistance
Fabiola Martin1, John Lee2, Emma Thomson3, Nick Tarrant4,
Antony Hale5 and Charles J Lacey1
Abstract
In the UK, patients undergo HIV viral load and genotype testing before they are prescribed antiretroviral therapy. The
genotype test guides clinicians in prescribing antiretroviral therapy with maximum efficacy against the patient’s specific
viral strain. HIV viral load escape under antiretroviral drug therapy, to which the virus was thought to be genotypically
susceptible, is commonly observed in patients with poor adherence. We observed early viral escapes in two-newly
diagnosed patients, during antiretroviral treatment, with different sequences compared to their original viral resistance
test and who reported excellent adherence to and tolerance of their therapy. HIV superinfection with a new viral strain
was identified in a patient with multiple risk factors and co-infections with sexually transmitted infections. The second
patient was a case of the emergence of primary resistant virus under drug pressure. Both suppressed their virus
promptly after treatment switch.
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Case 1
A 41-year-old, White British, man who has sex with men
(MSM) presented complaining of drenching night
sweats and fatigue of recent onset. He reported unpro-
tected oral and anal intercourse with casual partners and
had recently been diagnosed with hepatitis C virus
(HCV). He gave no travel history of note. He was diag-
nosed with and treated for early, secondary syphilis. His
HCV genotype was 1a (HCV RNA: 3.87 104 copies/
mL) and his HIV serology testing was negative. Four
weeks later, he presented with night sweats, anorexia
and dysphagia. Oesophageal candidiasis was suspected
and treated with ﬂuconazole 50mg once daily for seven
days. HIV-1 antibodies were positive (HIV viral load
[VL]: 10 million copies/mL, Log10 >5.8, CD4 count:
263 106/L, 21%). Acute HIV sero-conversion syn-
drome was diagnosed. Sequencing of protease (PR)
and ﬁrst 234 amino acids of the reverse transcriptase
(RT) genes indicated a fully antiretroviral-susceptible
HIV-1 subtype B strain with minor PR and RT diﬀer-
ences to the HIV reference strain HXB2 (K20R, E35D,
N37E, L63P; V8I, V90I, I142T, S162D, I178M). HCV
RNA was undetectable, suggesting spontaneous clear-
ance of the HCV. Sixteen weeks later, despite initial
recovery, the CD4 had declined to 185 106/L (12%).
The HIV-1 VL was 167,200 copies/mL (Log10 5.2).
Abacavir, lamivudine and nevirapine were commenced
and the VL suppressed to 270 copies /mL (Log10 2.4)
at 12 weeks. Four weeks later, the patient presented feel-
ing unwell with night sweats. On examination, he had
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right-sided inguinal lymphadenopathy and enlarged
liver and a palpable spleen. A pale macular rash was
visible on the trunk and extremities. He was diagnosed
with rectal Neisseria gonorrhoeae and urethral
Chlamydia trachomatis, his HCV RNA remained nega-
tive. However, the HIVVL had risen to 14,900 copies/ml
(Log10 4.2) despite good reported adherence and toler-
ance. HIV genotyping revealed HIV-1 subtype B with
multiple new mutations: PR: K14R, R83K, RT: A98S,
K101E, M184I, G190A, T215D, I135T, D177E, I178L,
V179I, T200A, I202V, Q207K, R211K. This virus,
showed high-level resistance to lamivudine and nevira-
pine and low-level resistance to abacavir. The sequences
were highly divergent exhibiting 45 nucleotide diﬀer-
ences of which 20 were non-synonymous including the
four resistance-associated mutations (Figure 1).
Considering the history of repeated unprotected sex
and co-infections with sexually transmitted infections
together with the number of changes in non-resistance
mutations HIV superinfection was suspected. This was
conﬁrmed by phylogenetic analysis. Highly active anti-
retroviral therapy (HAART) was changed to abacavir,
lamivudine, zidovudine and boosted atazanavir. The
HIV VL was <50 copies/mL (log10 1.6) within three
weeks. Fifteen months later, routine tests revealed
newly raised AST (73IU/L) and bilirubin (89 mmol/L)
levels and HCV RNA levels of 2.6 106 copies/mL. The
two HCV strains were identical in the 135 base region of
the 5’ NCR. Considering the previous HCV RNA nega-
tive tests and ongoing unprotected sex, HCV reinfection
was thought to be more likely than reactivation.
Case 2
A 41-year-old, White British MSM receiving treatment
for Pneumocystis jiroveci pneumonia was diagnosed
with HIV. The virus was subtype B and fully antiretro-
viral susceptible (VL 260,000 copies/mL, log10 5.4, CD4
count 4 106/L, 2.5%). He was commenced on tenofo-
vir, emtricitabine and efavirenz. He improved clinically,
but the CD4 count plateaued at 11 106/L, 2.6%) and
the VL only decreased to 88,000 copies/mL (log10 4.9) at
4 weeks and stalled at 56,000 copies/mL (log10 4.7) at 12
weeks. He reported no side-eﬀects, no new sexual con-
tacts and 100% adherence to HAART. He gave no
travel history of note. Resistance testing revealed
K65KR, M184V, K101E, Y181CY and G190CS.
Comparison of the two sequences revealed only four
out of 1007 sequences nucleotide changes between base-
line and the second test, excluding residues exhibiting
mixed bases, of which three resulted in amino acid
changes within known resistance foci at RT residues
101, 184 and 190. The fourth was a synonymous nucleo-
tide change. Based on the fact that the patient denied
lack of exposure, reported good adherence and the
commonly under drug pressure observed mutations,
this lack of suﬃcient VL response was thought to be
due to an unmasking of a primary minority species
virus under drug pressure, rather than HIV superinfec-
tion. The patient’s treatment was switched to zidovu-
dine, lamivudine, raltegravir and boosted darunavir.
Twenty-four weeks later he was feeling well and his
VL was 41 copies/mL (log10 1.6) and his CD4 count
155 106/L, 17%.
Discussion
We report viral escape as a consequence of potential
transmitted drug resistance due to HIV-1 superinfec-
tion and the unmasking of a primary minority species
resistant virus under drug pressure. In both case, viral
drug resistance was discovered following an insuﬃcient
immunological and virological response. Both patients
had received information on transmission and preven-
tion of sexually transmitted infections as well as HIV
superinfection and adherence to and side-eﬀects of anti-
retroviral medication. We routinely provide free
condoms and advise to refrain from sex during the
sero-conversion period.
Poor adherence, ineﬀective HAART, HIV super-
infection and unmasking of primary resistant mutants
are known to be associated with lack of suﬃcient viro-
logical response.1 The latter two are rare but should be
considered in patients with good adherence to
HAART. A detailed history and HIV VL measure-
ment, genotype and phylogenetic analysis, especially
ultradeep pyrosequencing,2 are useful in distinguishing
the cause of viral escape. HIV superinfection with a
diﬀerent virus can be acquired after primary serocon-
version.3,4 It is associated with early HIV infection5,6
and estimated to occur at a rate of around 5 per 100
person-years.2 It may lead to the acquisition of drug
resistance,7 viral escape, may necessitate treatment
switch and be associated with disease progression.8 In
our case, repeat genotyping detected the distinctly dif-
ferent new virus and guided a successful treatment
switch. We believe that the archived resistance in case
2 was 194V and 101E as these were not present in mix-
tures and that 65R and 181C then rapidly emerged as
indicated by these being mixed with wild type. The resi-
due at 190 was also mixed but not with wild type, and
we cannot be sure whether one or both of these were
archived or emerged in diﬀerent quasi-species. We were
not able to conduct ultradeep sequencing, since it is not
yet validated at our routine virology service. However,
the high divergence in the ﬁrst case and the lack of
divergence in the second case make superinfection in
the ﬁrst case and the unmasking of a previous resistant
variant in the second case, the most likely explanation
(Figure 1).
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Random samples of treatment-naı¨ve HIV-infected
subjects harboured 5%, 3% and 3% primary resistant
HIV strains to NNRTIs, NRTIs and PIs, respectively.9
In the absence of drug pressure, the mutated virus may
revert back to wild-type and not be detectable with
simple genotyping.10,11 The overall rate of loss of muta-
tions was reported to be 18 per 10 person-years follow-
up, with large variation in the loss of NRTI mutations
(M184V rapid, M41L & thymidine analogue mutations
[TAMs] stable) over time and a more rapid loss of
NNRTI and PI mutations compared to TAMs.12
Using these data, in our second case, the M184V
and Y181C may have been lost quicker than the
remaining three; however, they re-emerged under drug
pressure.
We support the current practice:13 advising patients
to avoid unprotected sex, measuring VL at baseline at
4, 8, 12 and 24 weeks, tailoring treatment to the viral
Figure 1. Molecular phylogenetic analysis by maximum likelihood method. Branches derived from Case 1 are shown in red while
those from Case 2 are shown in blue. Branches in black were derived from reference sequences obtained from the NCBI database.
The evolutionary history was inferred by using the maximum likelihood method based on the General Time Reversible model.14 The
tree with the highest log likelihood (7594. 0650) is shown. The percentage of trees in which the associated taxa clustered together is
shown next to the branches. Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ
algorithms to a matrix of pair-wise distances estimated using the maximum composite likelihood approach and then selecting the
topology with superior log likelihood value. A discrete Gamma distribution was used to model evolutionary rate differences among
sites (five categories [þG, parameter ¼ 0.2316]). The rate variation model allowed for some sites to be evolutionarily invariable ([þI],
51.4057% sites). The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The analysis
involved 104 nucleotide sequences. Codon positions included were 1stþ2ndþ3rdþNon-coding. All positions with less than 95% site
coverage were eliminated. That is, fewer than 5% alignment gaps, missing data and ambiguous bases were allowed at any position.
There were a total of 1006 positions in the final dataset. Evolutionary analyses were conducted in MEGA6.15 Bootstrap values >70%
are illustrated on the tree (1000 bootstrap replicates). Final editing was carried out using Figtree v1.4.2.
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genotype, repeating genotype in viral escape and
switching treatment in response to the new genotype.
Consent
Both patients have consented for the cases to be
published.
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